Alex­ion hit by sur­prise in­ter partes re­view as Am­gen chal­lenges Soliris patents

Am­gen is com­ing for Alex­ion — but not in the form of a ru­mored, and large­ly dis­pelled, takeover.

Rather, the US Patent Tri­als Ap­peal Board (PT­AB) has agreed to con­duct an in­ter partes re­view on Alex­ion’s Soliris. Am­gen, which is push­ing a biosim­i­lar to the com­ple­ment in­hibitor, filed the IPR in an ef­fort to over­turn patents on the com­po­si­tion eculizum­ab (the ac­tive in­gre­di­ent in Soliris), its for­mu­la­tion, and its use to treat cer­tain dis­eases, in­clud­ing the key in­di­ca­tion of parox­ys­mal noc­tur­nal he­mo­glo­bin­uria.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER